Industrial Transformation Research Hubs - Grant ID: IH220100017
Funder
Australian Research Council
Funding Amount
$4,808,669.00
Summary
ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The progra ....ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.Read moreRead less
Enhancing biopharmaceuticals: A disruptive bioseparation resin technology. This project aims to develop an innovative and disruptive platform technology for designing and manufacturing tailor-made high-performance bioseparation resins to enhance biopharmaceuticals manufacturing. Bacterial cell factories will be developed to enable biotechnological production of innovative polyester bead-based bioseparation resins, which will revolutionise manufacturing of biopharmaceuticals. Expected outcomes o ....Enhancing biopharmaceuticals: A disruptive bioseparation resin technology. This project aims to develop an innovative and disruptive platform technology for designing and manufacturing tailor-made high-performance bioseparation resins to enhance biopharmaceuticals manufacturing. Bacterial cell factories will be developed to enable biotechnological production of innovative polyester bead-based bioseparation resins, which will revolutionise manufacturing of biopharmaceuticals. Expected outcomes of this project are cost-effective and strongly enhanced approaches for biopharmaceuticals recovery, thereby providing significant benefits to accelerate research and development in early stage discovery and manufacture of biologics, therapeutic proteins and vaccines.Read moreRead less
Pharmacology Of Potential Anti-Tumour Agents: Iron Chelators Of The BpT Class
Funder
National Health and Medical Research Council
Funding Amount
$585,455.00
Summary
Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Renewal, we will perform pharmacological and preclinical studies to promote the development of BpT chelators as novel anti-tumour agents.
Improving Treatment Strategies For Chronic Alphaviral Arthritic Diseases
Funder
National Health and Medical Research Council
Funding Amount
$643,624.00
Summary
Chikungunya virus and Ross River virus cause epidemics of acute and chronic arthritic disease in humans, which is often poorly managed with current treatments. This grant seeks to understand the mechanisms that give rise to disease in order to identify improved treatment strategies. Both the persistence of viral replication in joint tissues and unnecessary inflammatory responses appear to be important factors driving chronic disease.
Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
Driving Change: Using Emergency Department Data To Reduce Alcohol-related Harm
Funder
National Health and Medical Research Council
Funding Amount
$1,468,026.00
Summary
The proposed project is a system change within partner emergency departments, providing them the information and tools to act on both risky alcohol consumption in individual patients and the sources of alcohol in the community which cause the harm they experience. Most importantly, the proposed public health interventions act as a tool for emergency departments to regularly raise awareness with the public and policymakers regarding the impact of alcohol on patients, clinicians and hospitals.
Eliminating Hepatitis C Transmission By Enhancing Hepatitis C Care And Treatment In Primary Health Care Settings.
Funder
National Health and Medical Research Council
Funding Amount
$1,221,831.00
Summary
In developed countries, people who inject drugs (PWID) are the group at greatest risk of hepatitis C (HCV) infection but few PWID receive HCV treatment. With the advent of highly effective non-interferon based treatments HCV elimination, although ambitious, is now being seriously considered globally. This partnership grant will explore the feasibility of eliminating HCV transmission by enhancing HCV care and treatment for PWID in primary health care settings.
Industrial Transformation Training Centres - Grant ID: IC170100035
Funder
Australian Research Council
Funding Amount
$4,743,710.00
Summary
ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to devel ....ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to develop ‘smart’ probes and ‘smart’ scanning, harnessing the digital revolution for better, cost effective diagnostic imaging and improved health outcomes.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE130100164
Funder
Australian Research Council
Funding Amount
$310,000.00
Summary
A facility for ex-vivo molecular imaging. The facility will allow a consortium of Australian researchers to create an integrated facility for imaging biological receptors in tissue, bringing together laboratory, radiochemistry and imaging expertise. Digital data at each site will be able to be viewed and analysed remotely.
Mid-Career Industry Fellowships - Grant ID: IM230100154
Funder
Australian Research Council
Funding Amount
$1,049,904.00
Summary
Fungi Power: Designer Fungal Cell Factories for Advanced Biomanufacturing. This project aims to build an advanced biomanufacturing platform based on filamentous fungi in collaboration with industry. Using synthetic biology, the project expects to engineer superior fungal host strains customisable to the needs of the industry and to address their technological gaps. The expected outcomes include the development of cost-efficient and sustainable fungal-based bioprocesses for the companies to produ ....Fungi Power: Designer Fungal Cell Factories for Advanced Biomanufacturing. This project aims to build an advanced biomanufacturing platform based on filamentous fungi in collaboration with industry. Using synthetic biology, the project expects to engineer superior fungal host strains customisable to the needs of the industry and to address their technological gaps. The expected outcomes include the development of cost-efficient and sustainable fungal-based bioprocesses for the companies to produce products, such as fine chemicals, pharmaceutical actives and food ingredients. The project would provide significant benefits by enabling existing and emerging companies' commercial successes and competitiveness in global markets, creating new jobs and resulting in the growth of the bio-economy in Australia.Read moreRead less